Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 1, 2007
Prenatal choline availability modulates hippocampal and cerebral cortical gene expressionTiffany J Mellott, Maximillian T Follettie, Veronica Diesl, et al.Journal of Endotoxin Research|August 26, 2003
Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophagesJian Jun Gao, Veronica Diesl, Tatiana Wittmann, et al.Journal of Leukocyte Biology|December 19, 2002
Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharideJian Jun Gao, Veronica Diesl, Tatiana Wittmann, et al.Cancer Research|November 18, 2008
IkappaBalpha kinase inhibitor IKI-1 conferred tumor necrosis factor alpha sensitivity to pancreatic cancer cells and a xenograft tumor modelYixian Zhang, Maria Gavriil, Judy Lucas, et al.Proceedings of the National Academy of Sciences of the United States of America|May 5, 2005
Bone morphogenetic protein 9 induces the transcriptome of basal forebrain cholinergic neuronsIgnacio Lopez-Coviella, Maximillian T Follettie, Tiffany J Mellott, et al.Molecular Cancer Therapeutics|June 11, 2009
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenograftsWells A Messersmith, N V Rajeshkumar, Aik Choon Tan, et al.Oncotarget|February 12, 2015
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growthAnthony M Barsotti, Michael Ryskin, Wenyan Zhong, et al.Journal of Medicinal Chemistry|December 23, 2009
Design and synthesis of novel diaminoquinazolines with in vivo efficacy for beta-catenin/T-cell transcriptional factor 4 pathway inhibitionChristoph M Dehnhardt, Aranapakam M Venkatesan, Zecheng Chen, et al.Molecular Cancer Therapeutics|February 4, 2015
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsFrank Loganzo, Xingzhi Tan, Matthew Sung, et al.The Journal of Pharmacology and Experimental Therapeutics|December 16, 2011
Osteogenic effects of a potent Src-over-Abl-selective kinase inhibitor in the mouseRichard J Murrills, Shoichi Fukayama, Frank Boschelli, et al.Pageof 2